title: [The IKKε kinase in breast cancer: from oncogenesis to treatment resistance].
abstract: The IKKε kinase, an atypical member of the IKK family of kinases, was recently identified as an oncogene overexpressed in over 30% of breast cancers. Besides its role in the regulation of the NF-κB transcription factor, which is well recognized for its implication in the development of breast cancers, IKKε was shown to phosphorylate numerous targets. Analysis of the phosphorylation of some of these substrates in the context of breast cancer highlighted new oncogenic signaling pathways that constitute potential targets for new therapies. Interestingly, IKKε is involved in the development of resistance to Tamoxifène. Thus, IKKε is a promising therapeutic target for newly developed breast cancer treatment.
authors: Chaire de recherche du Canada en signalisation et infections virales, centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Hôpital Saint-Luc, 264, boulevard René Lévesque Est, PEA 311 Montréal (Québec), H2X 1P1, Canada. nathalie.grandvaux@umontreal.ca
authors: Nathalie
authors: N
authors: Grandvaux
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000235:genetics / Q000378:metabolism*; D002471:Cell Transformation, Neoplastic; D000074749:Deubiquitinating Enzyme CYLD; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D020672:I-kappa B Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000172:deficiency / Q000502:physiology*; D051379:Mice; D008954:Models, Biological; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D009857:Oncogenes; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D017434:Protein Structure, Tertiary; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000172:deficiency / Q000502:physiology*; D015398:Signal Transduction; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use; D014157:Transcription Factors / Q000502:physiology; D025521:Tumor Suppressor Proteins / Q000378:metabolism
chemical_list: D018931:Antineoplastic Agents, Hormonal; D020672:I-kappa B Proteins; C105627:NFKBIE protein, human; D009363:Neoplasm Proteins; C491366:Nfkbie protein, mouse; D011518:Proto-Oncogene Proteins; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; D013629:Tamoxifen; C409984:CYLD protein, human; D000074749:Deubiquitinating Enzyme CYLD